89bio reports second quarter 2020 financial results and provides corporate update

89bio reports second quarter 2020 financial results and provides corporate update.bio89-100's phase 2 shtg trial is expected to be initiated in q3.topline results from bio89-100's phase 1b/2a nash trial are expected in late q3 to early q4.qtrly loss per share $0.85.q2 earnings per share view $-0.84 -- refinitiv ibes data.

ETNB Ratings Summary

ETNB Quant Ranking